Align Technology secured a significant patent victory in Europe on October 16, 2026, when the Unified Patent Court ruled that Angelalign Technology units infringe an orthodontic aligner patent.
The Paris Local Division of the Unified Patent Court delivered a decisive ruling finding that aligner systems incorporating Torque Ridges feature infringe Align’s European Patent EP 2 237 738 B1, which covers the company’s Power Ridge technology used within the Invisalign System of clear aligners. The court rejected Angelalign’s validity challenges, issued an injunction ordering the recall and destruction of infringing products, and instructed the company to pay damages.
The ruling represents a significant victory for Align and underscores the importance of protecting the innovations resulting from Align’s substantial and sustained investment in research and development,
Hsieh said in a statement.
European Market Restrictions and Product Replacements
The ruling remains subject to appeal.
Angelalign responded by emphasizing that the disputed feature had already been phased out in Europe. In September 2026, the company replaced Torque Ridges with an upgraded feature known as Pressure Points, designed to improve torque control without utilizing the contested design.
Our priority is to ensure that orthodontists can continue delivering excellent care to their patients.
Xavier Cherbavaz, general manager and vice president, Europe, Africa, and the Middle East, via Orthodontic Products
Cherbavaz added that Torque Ridges has already been retired in Europe and replaced with Pressure Points, an approach intended to support controlled force application and tooth contact.
Corporate Response and Global Litigation Timeline
While expressing respectful disagreement with the court’s reasoning, Angelalign confirmed it would comply with the remedial orders, including returning affected merchandise. Richard Hirschland, chief commercial officer and senior vice president, maintained that the firm respects intellectual property standards.
Angel takes intellectual property rights seriously and is careful not to infringe on valid patents.
Richard Hirschland, chief commercial officer and senior vice president, via Orthodontic Products
Hirschland noted that the company is reviewing the legal reasoning and will consider all available avenues while continuing to innovate and improve its products to benefit its providers and their patients despite litigation by a competitor.
Company representatives confirmed that the ruling does not affect operations in Spain, the United Kingdom, or markets outside Europe, such as the Americas and Asia.
The October 16 decision is part of an ongoing multi-jurisdictional intellectual property dispute initiated by Align in August 2025.
- February 2026: The Unified Patent Court issued a preliminary injunction requiring Angelalign to halt infringement of Align’s ClinCheck Live Update technology, a decision later upheld on appeal.
- July 2026: The U.S. International Trade Commission conducted an evidentiary hearing concerning five patents asserted by Align.
- August 2026: The Jinan Intermediate People’s Court in China ruled that Angelalign’s MasterForce biomechanical simulation system and ATreat digital treatment design system infringe Align’s patent rights regarding premolar extraction solutions.
Market Valuation and Financial Standing for Align Technology
Financial analysts tracking Align Technology Inc. (NASDAQ: ALGN) note that the European court victory reinforces the company’s competitive moat in the orthodontic sector. With a market capitalization of $10.46 billion, Align trades at $147.31 per share, which sits approximately 34.4% below its GF Value estimate of $224.61.
The company maintains a GF Score of 85 out of 100, driven by strong profitability metrics and financial strength, including an Altman Z-Score of 4.56. Institutional ownership exceeds 100%, while corporate insiders have sold approximately $1.5 million worth of shares over the past 12 months with no reported insider purchases.
Ongoing Proceedings and Future Determinations
Legal proceedings across multiple international tribunals remain active. In the United States, Align expects an initial determination regarding its claims before the U.S. International Trade Commission in November 2026. Meanwhile, Angelalign has appealed the first-instance judgment issued by the Jinan Intermediate People’s Court in China, where additional patent infringement actions brought by Align continue to progress.